It removes 1 big problem, the CEO and all the past legal and financial baggage. The US is a long way from revenues with FDA forcing INDs. Split off the research entity with the US patent and continue protocol development with funding and IND LOIs funding.. Distribute equity FAIRLY to all stakeholders.